Brendan M. Lilley
Brendan M. Lilley has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
Annalise M. Peebles
Steadman Philippon Research Institute, Vail, CO, USA
3 shared publicationsAnthony A. Romeo
Department of Orthopaedic Surgery, DuPage Medical Group, Chicago, IL, USA
3 shared publications- Matthew T. Provencher
Steadman Philippon Research Institute Vail Colorado U.S.A.
3 shared publications - Patrick J. Denard
Southern Oregon Orthopedics, Medford, OR, USA
3 shared publications - Alexandra-Chloé Villani
Center for Immunology and Inflammatory Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
2 shared publications - Anna L. K. Gonye
Cancer Ecology Center, The Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA; Cellular and Molecular Medicine Graduate Program, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA
2 shared publications
Latest Publications
- Open Access
- 15 September 2023
- Published by Elsevier in JSES International
- Vol. 8 (1) , 104-110
Effect of osteophyte removal on simulated range of motion using 3-dimensional preoperative planning software for reverse total shoulder arthroplasty
- 15 September 2023
- Published by Elsevier in JSES International
- Vol. 8 (1) , 104-110
Open AccessEffect of osteophyte removal on simulated range of motion using 3-dimensional preoperative planning software for reverse total shoulder arthroplasty
- 10 January 2022
- Published by Elsevier in Journal of Shoulder and Elbow Surgery
- Vol. 31 (5) , 1073-1082
What is the deviation in 3D preoperative planning software? A systematic review of concordance between plan and actual implant in reverse total shoulder arthroplasty
- 10 January 2022
- Published by Elsevier in Journal of Shoulder and Elbow Surgery
- Vol. 31 (5) , 1073-1082
What is the deviation in 3D preoperative planning software? A systematic review of concordance between plan and actual implant in reverse total shoulder arthroplasty
- Open Access
- 3 January 2022
- Published by Elsevier in JSES Reviews, Reports, and Techniques
- Vol. 2 (2) , 125-130
Impact of fatty infiltration of the rotator cuff on reverse total shoulder arthroplasty outcomes: a systematic review
- 3 January 2022
- Published by Elsevier in JSES Reviews, Reports, and Techniques
- Vol. 2 (2) , 125-130
Open AccessImpact of fatty infiltration of the rotator cuff on reverse total shoulder arthroplasty outcomes: a systematic review
- Open Access
- 15 October 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 6 (64) , eabj2901
Early cross-coronavirus reactive signatures of humoral immunity against COVID-19
Preexisting cross-coronavirus immunity influences the early development of SARS-CoV-2 humoral immunity after COVID-19.
- 15 October 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 6 (64) , eabj2901
Open AccessEarly cross-coronavirus reactive signatures of humoral immunity against COVID-19
Preexisting cross-coronavirus immunity influences the early development of SARS-CoV-2 humoral immunity after COVID-19.
- 1 July 2021
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 131 (13)
SARS-CoV-2 viremia is associated with distinct proteomic pathways and predicts COVID-19 outcomes
BACKGROUND. SARS-CoV-2 plasma viremia has been associated with severe disease and death in COVID-19 in small-scale cohort studies. The mechanisms behind this association remain elusive. METHODS. We evaluated the relationship between SARS-CoV-2 viremia, disease outcome, and inflammatory and proteomic profiles in a cohort of COVID-19 emergency department participants. SARS-CoV-2 viral load was measured using a quantitative reverse transcription PCR–based platform. Proteomic data were generated with Proximity Extension Assay using the Olink platform. RESULTS. This study included 300 participants with nucleic acid test–confirmed COVID-19. Plasma SARS-CoV-2 viremia levels at the time of presentation predicted adverse disease outcomes, with an adjusted OR of 10.6 (95% CI 4.4–25.5, P < 0.001) for severe disease (mechanical ventilation and/or 28-day mortality) and 3.9 (95% CI 1.5–10.1, P = 0.006) for 28-day mortality. Proteomic analyses revealed prominent proteomic pathways associated with SARS-CoV-2 viremia, including upregulation of SARS-CoV-2 entry factors (ACE2, CTSL, FURIN), heightened markers of tissue damage to the lungs, gastrointestinal tract, and endothelium/vasculature, and alterations in coagulation pathways. CONCLUSION. These results highlight the cascade of vascular and tissue damage associated with SARS-CoV-2 plasma viremia that underlies its ability to predict COVID-19 disease outcomes. FUNDING. Mark and Lisa Schwartz; the National Institutes of Health (U19AI082630); the American Lung Association; the Executive Committee on Research at Massachusetts General Hospital; the Chan Zuckerberg Initiative; Arthur, Sandra, and Sarah Irving for the David P. Ryan, MD, Endowed Chair in Cancer Research; an EMBO Long-Term Fellowship (ALTF 486-2018); a Cancer Research Institute/Bristol Myers Squibb Fellowship (CRI2993); the Harvard Catalyst/Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, NIH awards UL1TR001102 and UL1TR002541-01); and by the Harvard University Center for AIDS Research (National Institute of Allergy and Infectious Diseases, 5P30AI060354).
- 1 July 2021
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 131 (13)
SARS-CoV-2 viremia is associated with distinct proteomic pathways and predicts COVID-19 outcomes
BACKGROUND. SARS-CoV-2 plasma viremia has been associated with severe disease and death in COVID-19 in small-scale cohort studies. The mechanisms behind this association remain elusive. METHODS. We evaluated the relationship between SARS-CoV-2 viremia, disease outcome, and inflammatory and proteomic profiles in a cohort of COVID-19 emergency department participants. SARS-CoV-2 viral load was measured using a quantitative reverse transcription PCR–based platform. Proteomic data were generated with Proximity Extension Assay using the Olink platform. RESULTS. This study included 300 participants with nucleic acid test–confirmed COVID-19. Plasma SARS-CoV-2 viremia levels at the time of presentation predicted adverse disease outcomes, with an adjusted OR of 10.6 (95% CI 4.4–25.5, P < 0.001) for severe disease (mechanical ventilation and/or 28-day mortality) and 3.9 (95% CI 1.5–10.1, P = 0.006) for 28-day mortality. Proteomic analyses revealed prominent proteomic pathways associated with SARS-CoV-2 viremia, including upregulation of SARS-CoV-2 entry factors (ACE2, CTSL, FURIN), heightened markers of tissue damage to the lungs, gastrointestinal tract, and endothelium/vasculature, and alterations in coagulation pathways. CONCLUSION. These results highlight the cascade of vascular and tissue damage associated with SARS-CoV-2 plasma viremia that underlies its ability to predict COVID-19 disease outcomes. FUNDING. Mark and Lisa Schwartz; the National Institutes of Health (U19AI082630); the American Lung Association; the Executive Committee on Research at Massachusetts General Hospital; the Chan Zuckerberg Initiative; Arthur, Sandra, and Sarah Irving for the David P. Ryan, MD, Endowed Chair in Cancer Research; an EMBO Long-Term Fellowship (ALTF 486-2018); a Cancer Research Institute/Bristol Myers Squibb Fellowship (CRI2993); the Harvard Catalyst/Harvard Clinical and Translational Science Center (National Center for Advancing Translational Sciences, NIH awards UL1TR001102 and UL1TR002541-01); and by the Harvard University Center for AIDS Research (National Institute of Allergy and Infectious Diseases, 5P30AI060354).